Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

Blonde, L

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. [electronic resource] - Diabetes, obesity & metabolism Jul 2006 - 436-47 p. digital

Publication Type: Journal Article; Randomized Controlled Trial

1462-8902

10.1111/j.1463-1326.2006.00602.x doi


Adolescent
Adult
Aged
Blood Glucose--metabolism
Blood Pressure
Body Weight--drug effects
Cardiovascular Diseases--etiology
Diabetes Mellitus, Type 2--blood
Diabetic Angiopathies--blood
Double-Blind Method
Drug Therapy, Combination
Exenatide
Female
Glycated Hemoglobin--metabolism
Humans
Hypoglycemic Agents--adverse effects
Lipids--blood
Male
Metformin--therapeutic use
Middle Aged
Overweight
Peptides--adverse effects
Risk Factors
Sulfonylurea Compounds--therapeutic use
Venoms--adverse effects
Weight Loss--drug effects